ABBV

SEC source: 0001179110-21-011176 · edgar.xml · nonDerivative · entry 2

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,505

SEC source: 0001179110-21-011176 · edgar.xml · nonDerivative · entry 1

Durkin Brian L · CIK 0001756865 · VP, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-011172 · edgar.xml · derivative · entry 6

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,450 shares

Expires 2026-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-011172 · edgar.xml · derivative · entry 5

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 103,220 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-011172 · edgar.xml · nonDerivative · entry 4

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,003

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.56 to $131.09, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-011172 · edgar.xml · nonDerivative · entry 3

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,117

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.56 to $130.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-011172 · edgar.xml · nonDerivative · entry 2

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,673

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-011172 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-011109 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,104

SEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 3

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 2

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,229

SEC source: 0001179110-21-010956 · edgar.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,256

SEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,458

SEC source: 0001179110-21-010830 · edgar.xml · derivative · entry 7

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,050

Underlying: Common Stock · 174,100 shares

Expires 2027-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,597

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.19 to $123.48 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 486,221

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.19 to $123.18 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-010830 · edgar.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-010695 · edgar.xml · derivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common stock · 50,350 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-010695 · edgar.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001179110-21-010695 · edgar.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, Chief HR Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-009885 · edgar.xml · nonDerivative · entry 4

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,284

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.09 to $117.40 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-009885 · edgar.xml · nonDerivative · entry 3

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,284

SEC source: 0001179110-21-009885 · edgar.xml · nonDerivative · entry 2

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,128

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.73 to $116.47 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-009885 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,128

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.73 to $117.48 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-009160 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,068

Underlying: Common Stock · 66 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-009161 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,506

Underlying: Common Stock · 266 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-009162 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,941

Underlying: Common Stock · 326 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-008720 · edgar.xml · nonDerivative · entry 2

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · In trust

Disclosed balance after: 78,500

F1 · balance_after: The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.

SEC source: 0001179110-21-008720 · edgar.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · EVP, Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,711

SEC source: 0001179110-21-008721 · edgar.xml · nonDerivative · entry 1

Schumacher Laura J · CIK 0001319245 · Vice Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,003

SEC source: 0001179110-21-008421 · edgar.xml · derivative · entry 4

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,080 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 3

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,595

SEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 2

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,595

SEC source: 0001179110-21-008422 · edgar.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,047

SEC source: 0001179110-21-007282 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,914

Underlying: Common Stock · 63 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-007283 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,944

Underlying: Common Stock · 284 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The cash equivalent of 1,748 stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on May 1, 2021. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The cash equivalent of 1,748 stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on May 1, 2021. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-007284 · edgar.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,390

Underlying: Common Stock · 312 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-21-005980 · edgar.xml · derivative · entry 8

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 74,520 shares

Expires 2023-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-005980 · edgar.xml · derivative · entry 7

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,400 shares

Expires 2022-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 4

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,284

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 3

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,341

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 2

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-005980 · edgar.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-21-005245 · edgar.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,104

SEC source: 0001179110-21-005196 · edgar.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & Pres Global Allerg Aesth

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,991

SEC source: 0001179110-21-005197 · edgar.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,121

F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-21-005199 · edgar.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,128

F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-21-005200 · edgar.xml · nonDerivative · entry 1

BURNSIDE WILLIAM H.L. · CIK 0001563579 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,562

F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001179110-21-005202 · edgar.xml · nonDerivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,683

F1 · shares: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).